Drug Trial Radar · NCT00291642
A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen
Last checked: Nov 20, 2026Latest source record: Sep 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
551
Actual
Start
Jan 1, 2006
Primary completion
Apr 1, 2006
Study completion Apr 1, 2006
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Feb 14, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the efficacy comparability of cetirizine and levocetirizine, by comparing the effects of single intake of the two drugs to placebo in reducing symptoms of seasonal allergic rhinitis (SAR) in ragweed sensitive adult subjects exposed to ragweed pollen in an Environmental Exposure Unit.
Conditions
- Rhinitis
- Allergic
- Seasonal
Interventions
Placebo dropsDrug
* Pharmaceutical form: Drops for oral administration * Route of administration: Oral use
Placebo tablets matching to levocetirizineDrug
* Pharmaceutical form: Tablets for oral administration * Route of administration: Oral use
Placebo tablets matching to cetirizineDrug
* Pharmaceutical form: Tablets for oral administration * Route of administration: Oral use
Levocetirizine dropsDrug
* Pharmaceutical form: Drops for oral administration * Concentration: 5 mg/ml * Route of administration: Oral use
Levocetirizine tabletsDrug
* Pharmaceutical form: Tablets for oral administration * Concentration: 5 mg * Route of administration: Oral use
Cetirizine dropsDrug
* Pharmaceutical form: Drops for oral administration * Concentration: 10 mg/ml * Route of administration: Oral use
Cetirizine tabletsDrug
* Pharmaceutical form: Tablets for oral administration * Concentration: 10 mg * Route of administration: Oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Major Symptom Complex (MSC) Score Over Period ITime frame: Baseline, Treatment Period 1 [Day 1, from drug intake (at 11:00 am) to 5 hours post-treatment (at 4:00 pm)]
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Kingston, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.